UCB (OTCMKTS:UCBJY) Upgraded to “Hold” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of UCB (OTCMKTS:UCBJY) from a moderate sell rating to a hold rating in a research note released on Monday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the company. Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Zacks Research raised UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

UCB Stock Performance

Shares of OTCMKTS:UCBJY opened at $127.41 on Monday. UCB has a 52 week low of $106.09 and a 52 week high of $168.76. The company has a 50-day moving average price of $143.25 and a 200 day moving average price of $147.27. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.